Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade D 14.24 1.06% 0.15
ATNX closed up 1.06 percent on Friday, September 20, 2019, on 4.77 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Up
See historical ATNX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
New Downtrend Bearish 0.00%
200 DMA Support Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
20 DMA Resistance Bearish 1.06%
Shooting Star Candlestick Bearish 1.06%
Lizard Bearish Bearish Day Trade Setup 1.06%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.06%
New Uptrend Bullish 1.06%

Older signals for ATNX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Chemistry Organic Compounds Oncology Cancers Chemotherapy Organic Chemistry Antineoplastic Drugs Therapies For Cancer Pruritus Docetaxel Paclitaxel Scars Treatment Of Various Types Of Cancers
Is ATNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.11
52 Week Low 9.38
Average Volume 707,131
200-Day Moving Average 14.0289
50-Day Moving Average 16.1854
20-Day Moving Average 14.3815
10-Day Moving Average 14.037
Average True Range 0.8002
ADX 26.57
+DI 21.2464
-DI 21.3428
Chandelier Exit (Long, 3 ATRs ) 13.4694
Chandelier Exit (Short, 3 ATRs ) 15.9006
Upper Bollinger Band 15.4095
Lower Bollinger Band 13.3535
Percent B (%b) 0.43
BandWidth 14.296144
MACD Line -0.5293
MACD Signal Line -0.6394
MACD Histogram 0.1101
Fundamentals Value
Market Cap 812.58 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -4.10
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.16
Resistance 3 (R3) 15.10 14.75 15.00
Resistance 2 (R2) 14.75 14.51 14.77 14.95
Resistance 1 (R1) 14.49 14.37 14.62 14.55 14.90
Pivot Point 14.14 14.14 14.20 14.16 14.14
Support 1 (S1) 13.88 13.90 14.01 13.94 13.58
Support 2 (S2) 13.53 13.76 13.55 13.53
Support 3 (S3) 13.27 13.53 13.48
Support 4 (S4) 13.33